ArticleCancer medicine2025
Integrated Analysis of Single-Cell and Bulk RNA-Sequencing Defines N7-Methylguanosine (m7G)-Mediated Modifications' Role in Prognosis and the Tumor Immune Microenvironment in Hepatocellular Carcinoma.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRNA 7-Methylguanosine (m7G) modification is biologically important to tumorigenesis and progression. Knowledge regarding the effect of m7G modification on the clinical features of hepatocellular carcinoma and its prognosis, tumor immune microenvironment, and sensitivity to immunotherapy remains limited.
methodSingle-cell RNA sequencing (scRNA-seq) data was sourced from the GEO repository. Transcriptomic datasets were procured from TCGA, GEO, and ICGC databases. Following this, we scrutinized 17 m7G-associated genes and executed unsupervised clustering to discern m7G modification profiles within HCC. Evaluation of immune cell infiltration levels and associated biological functions across varied m7G modification patterns was conducted using single-sample gene set enrichment analysis (ssGSEA) complemented by gene set variation analysis (GSVA). In addition, we employed principal component analysis methodologies to elucidate m7G modification profiles in individual tumors and subsequently devised the m7Gscore. Data pertaining to m7G-related protein and mRNA levels were sourced from the Human Protein Atlas (HPA) database. These findings were corroborated in both HCC and normal samples utilizing western blot analysis, immunohistochemical assays, and RT-qPCR evaluations.
resultsOur analysis unveiled diverse cellular subgroups within HCC, with a particular focus on T-cell populations, providing insights into the intricate interplay of immune activation and suppression within the tumor microenvironment (TME). HCC patients were stratified into three distinct m7G modification patterns: immune-desert, immune-inflamed, and immune-excluded. Subsequently, m7Gscores, derived from m7G-associated signature genes, categorized HCC patients into high and low m7Gscore groups. Patients in the high-score cohort exhibited significantly improved survival outcomes compared to those in the low-score cohort. Elevated m7Gscores also correlated with enhanced therapeutic responsiveness, leading to improved outcomes in both chemotherapy and immunotherapy regimens. Our findings were further validated through RT-qPCR, western blot analyses, and immunohistochemical assays, providing robust support for our bioinformatic observations.
conclusionThe m7G modification profiles play a pivotal role in prognosticating outcomes for HCC patients, intricately intertwined with microenvironmental heterogeneity and complexity. Furthermore, the analytical insights gained from the m7Gscore signature not only shed light on tumor microenvironment infiltration dynamics but also strengthen prognostic precision, paving the way for optimizing immunotherapeutic approaches in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.